Exscientia Company Overview

Exscientia logo
Exscientia
Exscientia primary media

About Exscientia

Exscientia (NASDAQ:EXAI) specializes in leveraging artificial intelligence (AI) to accelerate drug discovery and development. By harnessing the power of AI, Exscientia aims to design molecules more efficiently than traditional methods, reducing the time and cost associated with bringing new medicines to market. The company's projects span a wide range of therapeutic areas, including Oncology, Immunology, and Cardiovascular diseases, with the objective of delivering highly targeted therapies that can improve patient outcomes. Through partnerships with pharmaceutical and biotechnology companies, Exscientia is working to revolutionize the field of drug discovery by making it faster, more effective, and accessible.

What is Exscientia known for?

Snapshot

2012
Year founded
482
Employees
Oxford, United Kingdom
Head office
Loading Map...

Operations

All Locations
United Kingdom of Great Britain and Northern Ireland

Products and/or services of Exscientia

  • Artificial intelligence-driven drug discovery platform designed to accelerate the creation of precision-engineered medicines.
  • Collaborations with leading pharmaceutical companies to design novel molecules for complex targets.
  • Data-driven precision oncology service, utilizing AI to identify potent anticancer therapies.
  • AI-based molecule screening for rapid identification of viable drug candidates.
  • Bespoke AI algorithms for predicting drug efficacy and safety profiles.
  • Digital chemistry solutions to streamline and optimize the medicinal chemistry process.

Exscientia executive team

  • Dr. David Hallett Ph.D.Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director
  • Mr. Ben R. TaylorCFO, Chief Strategy Officer & Executive Director
  • Dr. John P. Overington Ph.D.Chief Technology Officer
  • Ms. Sara ShermanVice President of Investor Relations
  • Mr. Dan IrelandExecutive VP of Legal & Company Secretary
  • Mr. Parker MossExecutive Vice President of Corporate Development
  • Ms. Caroline RowlandChief People Officer
  • Mr. Richard LawChief Business Officer
  • Mr. Nikolaus KrallExecutive Vice President of Precision Medicine
  • Dr. Marie-Louise Helena Fjallskog M.D., Ph.D.Interim Chief Medical Officer & Clinical Development Lead

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.